Life Science News

Bausch Health to Announce Fourth-Quarter and Full-Year 2022 Results on Feb. 23

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its fourth-quarter and full-year financial results on Thursday, Feb. 23, 2022. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call

Conference Call Details

Date:

Thurs., Feb. 23, 2023

Time:

8:00 a.m. U.S. EST

Webcast:

http://ir.bauschhealth.com/events-and-presentations

A replay of the conference call will be available on the investor relations website.

To participate in the live Q&A session, please register using this link to receive a PIN, which will be sent an hour before the conference call.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX:BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.

###

Investor Contact: Mark Maico, ir@bauschhealth.com,(877) 281-6642 (toll-free)

Media Contact: Kevin Wiggins, corporate.communications@bauschhealth.com,(908) 541-3785

SOURCE: Bausch Health Companies Inc.



View source version on accesswire.com:
https://www.accesswire.com/737551/Bausch-Health-to-Announce-Fourth-Quarter-and-Full-Year-2022-Results-on-Feb-23

News Provided by ACCESSWIRE via QuoteMedia

BHC:CA,BHC
The Conversation (0)

Talc Plaintiffs Will Press to Reopen Courthouse Doors

In denying Motion for Rehearing, Third Circuit affirms J&J's 'Texas Two-Step' bankruptcy
was not filed in good faith

The U.S. Court of Appeals for the Third Circuit has denied a request for a rehearing of the LTL bankruptcy petition, signaling a move to reopen litigation against Johnson & Johnson (NYSE:JNJ) based on claims that the company's talcum powder products are linked to ovarian cancer and mesothelioma.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Abbott: Clean, Accessible Water for a Healthy Future

Abbott

Water sustains life, health, and ecosystems. It's a vital resource for a global healthcare company striving to help people around the world live healthier, fuller lives.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Medtronic to boost AI innovation with new platform introduction

A strategic collaboration with Cosmo Pharmaceuticals and NVIDIA delivers the GI Genius™ AI Access™ platform designed to accelerate AI innovation for healthcare.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced Cosmo Pharmaceuticals and NVIDIA plan to integrate NVIDIA's AI technologies into the GI Genius™ intelligent endoscopy module — the first FDA-cleared, AI-assisted colonoscopy tool to help physicians detect polyps that can lead to colorectal cancer.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer

InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that it has promoted Andrea Tommasoli to Chief Operating Officer. Mr. Tommasoli formerly served as the Company's Senior Vice President of Global Sales & Marketing since joining InspireMD in November 2020.

"Andrea has been instrumental in expanding the footprint of CGuard EPS across our approved markets in the EU and, as we advance toward potential U.S. approval with our ongoing U.S. Investigational Device Exemption (IDE) clinical trial, and as our business requirements shift toward operational capacity to support our commercial growth, we believe his background and skill set make him an ideal candidate to assume the role of Chief Operating Officer of the Company at this important time," stated Marvin Slosman, Chief Executive Officer of InspireMD. "On behalf of the entire InspireMD team, I would like to congratulate Andrea on this promotion and look forward to his continued contributions."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

GeminiBio Appoints Industry Veteran Cory Stevenson as Executive Chairman

Gemini BioProducts Holding, Inc. ("GeminiBio" or the "Company"), a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida -based healthcare private equity firm, announced the appointment of Cory Stevenson as Executive Chairman of the Board of Directors.

(PRNewsfoto/BelHealth Investment Partners)

Mr. Stevenson joined the Board of GeminiBio in 2022 and has been working closely with the GeminiBio management team as they prepare to complete a three-phase buildout that addresses the long-term capacity needs in the biopharma and cell/gene therapy marketplace. Previously, Mr. Stevenson served as President of the BioProduction Division of Thermo Fisher Scientific (NYSE:TMO), a world leader in serving the biopharma sector, with annual revenue of more than $40 billion . During Cory's tenure, the BioProduction business grew from $200 million in revenues to over $2.5 billion annually.

Harold S. Blue , Managing Partner of BelHealth Investment Partners said, "We are fortunate to have Cory expand his role and guide our strategy at GeminiBio. Cory has been very helpful during the last year as a board member and I am excited that he will be taking a more active role. Also, given that Cory worked directly with GeminiBio's CEO, Brian Parker , while at Thermo Fisher, this was a natural fit."

Cory Stevenson , Executive Chairman of GeminiBio added, "I am delighted to expand my role at GeminiBio after working closely with Brian and the rest of the team since I joined the Board. With the completion of its 57,000-square-foot manufacturing facilities, GeminiBio is positioning itself as a vendor delivering much-needed critical solutions to the global biopharma industry. I am looking forward to this exciting next phase at GeminiBio."

About BelHealth Investment Partners

BelHealth Investment Partners, based in Fort Lauderdale, Florida , is a healthcare private equity firm focused on lower middle market companies. BelHealth has a unique combination of investing, executive management, and entrepreneurial experience. BelHealth acquires majority positions in entrepreneur-owned companies that it believes will benefit from its extensive operating and private equity investment expertise. For more information, visit www.belhealth.com .

About GeminiBio

Founded in 1985, GeminiBio serves the global biotechnology industry, from basic research to commercial production, with a focus on helping our customers accelerate the development of life enhancing biotherapeutics by streamlining and improving their cell culture and process liquid manufacturing workflows. The company's products are organized into two core verticals – Cell Culture Solutions and Process Liquid Solutions. Located in West Sacramento, California , GeminiBio has 57,000 square feet of cGMP manufacturing space that is segregated between animal origin free and animal component manufacturing. GeminiBio is an ISO 13485 certified, FDA registered Class 1 Medical Device Manufacturer, aligned with 21 CFR Part 820. For more information, visit www.geminibio.com .

Contact:
BelHealth: Inder Tallur , itallur@belhealth.com
GeminiBio: bparker@geminibio.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/geminibio-appoints-industry-veteran-cory-stevenson-as-executive-chairman-301774586.html

SOURCE BelHealth Investment Partners

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Notice of Knight Therapeutics' Fourth Quarter and Year End 2022 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2022 financial results on Thursday, March 23, 2023 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date : Thursday, March 23, 2023

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×